Navigation Links
Galderma Completes Acquisition of CollaGenex
Date:4/11/2008

LAUSANNE, Switzerland, April 11 /PRNewswire/ -- Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, today announced that its U.S. holding company, Galderma Laboratories, Inc., has completed its acquisition of CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI). As a result of the transaction, CollaGenex has become a wholly owned subsidiary of Galderma Laboratories.

"We are pleased to complete the acquisition process and are moving forward quickly to combine the two organizations to enable us to better serve dermatologists and the patients they serve," said Humberto C. Antunes, Chief Executive Officer of Galderma Pharma S.A. "CollaGenex's oral rosacea therapy will be an important complement to Galderma's topical products, and the two company's development pipelines have innovative compounds that have the potential to improve therapy and meet unmet needs."

CollaGenex's innovative products complement and enhance Galderma's portfolio for rosacea. Launched by CollaGenex in 2006 as the first FDA-approved systemic product, Oracea(R) is the only oral product indicated for the specific treatment of the inflammatory lesions of rosacea, and is a market leader in rosacea treatment products. Galderma's MetroGel(R) 1% is the leading topical drug for the treatment of inflammatory lesions of rosacea. Adding to this portfolio, Col-118 (brimonidine) is an innovative product under development for the treatment of erythema associated with rosacea.

Upon the closing of the acquisition, all remaining outstanding shares of CollaGenex common stock, other than those held by stockholders who properly perfect appraisal rights under Delaware law, were converted into the right to receive $16.60 per share in cash.

About Galderma

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Company has a p
'/>"/>

SOURCE Galderma Pharma S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
2. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Carrington Completes $8 Million Financing
5. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
6. New Brunswick Scientific Completes Merger Transaction with Eppendorf
7. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
8. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
9. Optherion, Inc. Completes $37 Million Start Up Financing
10. Companys Partner Completes Trial Production of a New Antiviral Medicine
11. American Oriental Bioengineering Completes Acquisition of Guangxi Boke Pharmaceutical Company Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Due to a misstatement posted ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... cell therapy research that might benefit ALS patients. Because ... new stem cell technologies and therapeutic applications, FRC listed ASCTC ... Challenge donors who wish not to support research that ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 SPIE Fellow ... Physics and Optical Science and Director of the Center ... North Carolina at Charlotte, and co-founder and Chairman of ... serve as the 2015 Vice President of SPIE, the ... President Philip Stahl announced recent election results at the ...
(Date:8/28/2014)... August 28, 2014 “This kit has an ... screen from 0 to 150 ppb,” said Mark Tess, PhD, ... significant benefit to plant owners and USDA-GIPSA inspection agencies that ... commodities. Testing can take place in a matter of minutes ... the plant test the feed and grain before accepting it, ...
(Date:8/28/2014)... NEW YORK , Aug. ... announces that a new market ... its catalogue: Whole ... (Systems, Kits (Library Preparation, Target ... Technology (Sequencing by Synthesis), by ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... SAN FRANCISCO, Calif., March 11 Raven,biotechnologies, inc., ... development of monoclonal antibody therapeutics (MAbs) for cancer,today ... RAV12 Phase,1/2a trial has been accepted as a ... the American Society of Clinical Oncology (ASCO).,The presentation ...
... in Western Pennsylvania Earn Designation, PITTSBURGH, March ... Allegheny General Hospital, UPMC Presbyterian Shadyside and UPMC,Passavant ... Cancers., Complex and rare cancers comprise approximately ... it difficult for patients to locate or,research facilities ...
... Ltd. has announced,development of a chemically synthesized vaccine ... its patented Replikins(TM) technology.,When the vaccine was administered ... lethal Taura virus. The specificity of the protective,effect ... the active,regions in the vaccine, and as a ...
Cached Biology Technology:Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO 2Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO 3Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus 2
(Date:8/31/2014)... release is available in French . ... study just published in the prestigious Nature Neuroscience ... Research Centre of the Douglas Mental Health University Institute and ... neural circuitry and dynamic mechanisms controlling memory as well of ... a sub-region named the subiculum. , In 2009, they ...
(Date:8/29/2014)... Until recently, little has been known about what ... international team of scientists, one of whom is a ... by showing that genes controlling the development of the ... rabbit domestication., The study was published Aug. 28 in ... questions. It is online at http://www.sciencemag.org/ ., The ...
(Date:8/29/2014)... of connections in transcription factor networks (TFNs) to evaluate ... published in PLOS Computational Biology in August. ... to a network,s resilience against mutations. , "In ... TFN models has a greater effect on robustness than ... said Dov A. Pechenick, PhD, lead author and former ...
Breaking Biology News(10 mins):Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2
... 26, 2010) Consumption of 100 percent fruit juice ... diet quality in children and teens, according to new ... meeting. Two new studies from researchers at the ... Medicine clearly highlight the benefits of drinking 100 percent ...
... On April 15, 2010 , Dr. Stipkala joined a panel ... hosted by the University of South Carolina ,s NanoCenter in ... capitalists from all over the Southeast who are active in the nanotechnology ... Dr. Stipkala and ...
... YELLOWKNIFE, NT APRIL 2010 High in the Mackenzie ... tools being revealed as warming temperatures melt patches of ice ... Tom Andrews, an archaeologist with the Prince of Wales ... International Polar Year Ice Patch Study, is amazed at the ...
Cached Biology News:Drinking 100 percent fruit juice is associated with improved diet quality in children 2Dr. Jeremy M. Stipkala, Patent Attorney, Speaks on USC NanoCenter Panel 2Ancient artifacts reveals as northern ice patches melt 2
... DEPC-treated Water is suitable ... is prepared by incubating with ... autoclaved to remove the DEPC.DNase/RNase-Free ... for use in all molecular ...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: